Biotech Values

[genisi]

>If ITMN-191 is clearly better than Telaprevir in terms of efficacy or tolerability, it will likely capture most of the Telaprevir business.<

I think that in addition to better efficacy or tolerability, if a next generation protease inhibitor has a dosing advantage, and/or can work in future HCV cocktails with other polymerase/protease inhibitors, it will be adopted (although, not to the "capture most of the Telaprevir business" extent).